BioNxt Solutions Inc.
VANCOUVER, BC / ACCESSWIRE / July 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a master services agreement ("MSA") with a German-based international contract research, development, and manufacturing organization (the "CRDMO"). The MSA will serve as the foundation for BioNxt's future product development, particularly its pipeline of oral dissolvable ("ODF") drug formulations.
With a head office in Munich, Germany, the CRDMO is an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches. The CRDMO also offers integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
"This is a very important step for our company," stated Wolfgang Probst, Interim CEO and Director of BioNxt. "With the recent success of our Cladribine ODF toxicity and comparative PK study, we are eager to advance the program to the next stage, namely the human comparative bioequivalence study. The MSA we just signed puts BioNxt in a position to satisfy all the necessary laboratory, technical, and regulatory steps toward clinical studies and product commercialization."
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MicroVision Collaborates with Leading Photonics Ecosystem to Acquire FMCW Lidar Business10.11.2025 22:05:00 CET | Press release
REDMOND, WA / ACCESS Newswire / November 10, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced that it had entered into an agreement to acquire the business and assets of Scantinel Photonics GmbH, a developer of 1550nm frequency-modulated continuous wave, or FMCW, lidar technology targeted for initial application in the commercial vehicle market. In connection with the acquisition, MicroVision is collaborating with certain funding and strategic partners to accelerate productization and commercial opportunities. Scantinel Photonic's core technology was developed with financial backing and key support from Zeiss Group, a German manufacturer of optical systems and optoelectronics; Scania, a Swedish commercial trucking OEM; and PhotonVentures, a deep tech venture capital firm purely focused on the key enabling technology of integrated photonics and a strategic partner of PhotonDelta, a Dutch distr
Loop Industries Executes a Multi-Year Offtake Agreement With Nike, the Global Leader in Athletic Footwear and Apparel10.11.2025 14:00:00 CET | Press release
Nike signs on as the anchor customer for the Infinite Loop™ India manufacturing facility. Multi-year offtake agreement secures supply of Twist™, Loop's branded, virgin-quality polyester resin made exclusively from textile waste. Twist™ will feature full traceability via Loop's proprietary chemical tracer technology, providing verifiable textile to textile recycled content. Infinite Loop India is a joint venture between Loop industries and Ester industries. MONTRÉAL, QUEBEC / ACCESS Newswire / November 10, 2025 / Loop Industries, Inc. (Nasdaq:LOOP) ("Loop"), a clean technology company accelerating the circular economy, today announced a multi-year offtake agreement with NIKE, Inc. ("Nike"), the global leader in athletic footwear and apparel. Under the agreement, Loop will supply Twist™, its virgin-quality circular polyester resin made exclusively from textile waste, establishing Nike as the anchor customer for the Infinite Loop™ India manufacturing facility which is being constructed in
EverC Introduces AI-powered Scam Network Intelligence to Disrupt Fraud Online10.11.2025 09:00:00 CET | Press release
The solution maps the entire scam infrastructure across e-commerce, social media, and payments marketplaces NEW YORK CITY, NY / ACCESS Newswire / November 10, 2025 / EverC, now part of G2 Risk Solutions, today announced Scam Network Intelligence, an AI-powered solution that exposes scam networks to help marketplaces detect and disrupt fraud. Scams are now the largest driver of fraud losses globally, accounting for 23% of fraudulent transactions in 2024, with losses reaching $1 trillion. To address the rise in fraud in the payments and e-commerce space, the Scam Network Intelligence solution gives marketplaces visibility into the networks behind online scams. The solution has the ability to identify and map how scammers reach and engage their victims-across ad networks, fake support portals, messaging apps, and social media networks. By identifying scam clusters early, the payments ecosystem can reduce blind spots and prevent consumer harm. "Fraud is increasingly sophisticated and flows
Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea7.11.2025 14:00:00 CET | Press release
New initiative in the Konkouré Delta builds on Senegal's success, advancing coastal restoration, biodiversity, and community resilience across West Africa. CONAKRY, GN / ACCESS Newswire / November 7, 2025 / Building on the success of its 7,000-hectare mangrove reforestation project in Senegal-which has already generated an estimated 2.8 million tonnes of CO₂ reductions and measurable community benefits-Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is expanding its blue carbon leadership into the Konkouré Delta of Guinea, as blue carbon emerges as a critical frontier for climate investment and coastal resilience. Developed through ALLCOT - A Karbon-X Company, the project development and advisory arm of Karbon-X, the initiative will replicate and scale the proven model from Senegal, enhancing biodiversity, shoreline protection, and sustainable livelihoods across West Africa. Mangroves are more than trees; they are natural shields protecting coastlines, nurseries for marine li
Innodata Reports Third Quarter 2025 Results6.11.2025 22:30:00 CET | Press release
Revenue up 20% Year-Over-Year Reiterates Prior Guidance of 45% or More YoY Growth in 2025 Anticipates Transformative Growth in 2026 Based on New Wins and Strong Momentum NEW YORK CITY, NY / ACCESS Newswire / November 6, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the third quarter ended September 30, 2025. Revenue of $62.6 million for the three months ended September 30, 2025, representing 20% year-over-year organic revenue growth. Revenue of $179.3 million for the nine months ended September 30, 2025, representing 61% year-over-year organic revenue growth. Adjusted EBITDA of $16.2 million for the three months ended September 30, 2025, an increase of $2.3 million, or 17%, from $13.9 million in the same period last year.* Adjusted EBITDA of $42.2 million for the nine months ended September 30, 2025, an increase of $21.8 million, or 106%, from $20.4 million in the same period last year.* Net income of $8.3 million, or $0.26 per basic share and $0.24 per diluted share, f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom